{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:15:27Z","timestamp":1787498127431,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The  National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82160565 to T.H.Y"],"award-info":[{"award-number":["82160565 to T.H.Y"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05146-7","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:57:58Z","timestamp":1774580278000},"page":"13497-13512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["YB-1 drives triple-negative breast cancer progression and paclitaxel resistance through Wnt\/\u03b2-catenin pathway"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"5146_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110073","volume":"85","author":"A Alkrekshi","year":"2021","unstructured":"Alkrekshi A, Wang W, Rana PS, Markovic V, Sossey-Alaoui K (2021) A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Cell Signal 85:110073. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110073","journal-title":"Cell Signal"},{"key":"5146_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065867","author":"A Bano","year":"2023","unstructured":"Bano A, Stevens JH, Modi PS, Gustafsson J, Strom AM (2023) Estrogen receptor \u03b24 regulates chemotherapy resistance and induces cancer stem cells in triple negative breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065867","journal-title":"Int J Mol Sci"},{"key":"5146_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051253","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z (2022a) Triple negative breast cancer: updates on classification and treatment in 2021. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14051253","journal-title":"Cancers (Basel)"},{"key":"5146_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051253","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M (2022) Triple negative breast cancer: updates on classification and treatment in 2021. Cancers. https:\/\/doi.org\/10.3390\/cancers14051253","journal-title":"Cancers"},{"key":"5146_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1356778","volume":"14","author":"S Cao","year":"2024","unstructured":"Cao S, Long X, Xiao L, Zhang P, Shen M, Chen F, Bao C, Zhong X, Luo T, Ye F (2024) DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting type I IFN-mediated signalling apoptosis. Front Oncol 14:1356778. https:\/\/doi.org\/10.3389\/fonc.2024.1356778","journal-title":"Front Oncol"},{"key":"5146_CR6","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2007-05-089151","volume":"111","author":"M Chatterjee","year":"2008","unstructured":"Chatterjee M, Rancso C, St\u00fchmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC (2008) The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111:3714\u20133722. https:\/\/doi.org\/10.1182\/blood-2007-05-089151","journal-title":"Blood"},{"key":"5146_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02388-8","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Han S, Chen J, Hu P, Zeng Z, Hu Y, Xiong H, Ke Z, Zhang Y, Xu F, Zhao G (2021) A reciprocal feedback of miR-548ac\/YB-1\/Snail induces EndMT of HUVECs during acidity microenvironment. Cancer Cell Int 21:692. https:\/\/doi.org\/10.1186\/s12935-021-02388-8","journal-title":"Cancer Cell Int"},{"key":"5146_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03462-z","volume":"20","author":"S Cocco","year":"2022","unstructured":"Cocco S, Leone A, Roca MS, Lombardi R, Piezzo M, Caputo R, Ciardiello C, Costantini S, Bruzzese F, Sisalli MJ, Budillon A, De Laurentiis M (2022) Inhibition of autophagy by chloroquine prevents resistance to PI3K\/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. J Transl Med 20:290. https:\/\/doi.org\/10.1186\/s12967-022-03462-z","journal-title":"J Transl Med"},{"key":"5146_CR9","first-page":"1715","volume":"35","author":"M Cybulski","year":"2015","unstructured":"Cybulski M, Jarosz B, Nowakowski A, Jeleniewicz W, Kutarska E, Bednarek W, Stepulak A (2015) Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer. Anticancer Res 35:1715\u20131721","journal-title":"Anticancer Res"},{"key":"5146_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101552","volume":"5","author":"A Dheeraj","year":"2024","unstructured":"Dheeraj A, Garcia Marques FJ, Tailor D, Bermudez A, Resendez A, Pandrala M, Grau B, Kumar P, Haley CB, Honkala A, Kujur P, Jeffrey SS, Pitteri S, Malhotra SV (2024) Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy. Cell Rep Med 5:101552. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101552","journal-title":"Cell Rep Med"},{"key":"5146_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01101-0","author":"H Dong","year":"2024","unstructured":"Dong H, Peng Z, Yu T, Xiong J (2024) YB-1 targeted by miR-509-3-5p affects migration and invasion of triple-negative breast cancer by regulating cellular epithelial-mesenchymal transition. Mol Biotechnol. https:\/\/doi.org\/10.1007\/s12033-024-01101-0","journal-title":"Mol Biotechnol"},{"key":"5146_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.681476","volume":"11","author":"M Ensenyat-Mendez","year":"2021","unstructured":"Ensenyat-Mendez M, Llin\u00e0s-Arias P, Orozco JIJ, \u00cd\u00f1iguez-Mu\u00f1oz S, Salomon MP, Ses\u00e9 B, DiNome ML, Marzese DM (2021) Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer. Front Oncol 11:681476. https:\/\/doi.org\/10.3389\/fonc.2021.681476","journal-title":"Front Oncol"},{"key":"5146_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166510","volume":"1868","author":"Y Guo","year":"2022","unstructured":"Guo Y, Xu X, Dong H, Shen B, Zhu J, Shen Z, Zhou C, Luo X, Qu Y, Cai X, Zhang Q, Lu L, Li F (2022) Loss of YB-1 alleviates liver fibrosis by suppressing epithelial-mesenchymal transition in hepatic progenitor cells. Biochim Biophys Acta Mol Basis Dis 1868:166510. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166510","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5146_CR14","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1074\/jbc.M208724200","volume":"278","author":"K Higashi","year":"2003","unstructured":"Higashi K, Inagaki Y, Suzuki N, Mitsui S, Mauviel A, Kaneko H, Nakatsuka I (2003) Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) collagen gene expression by interferon-gamma. J Biol Chem 278:5156\u20135162. https:\/\/doi.org\/10.1074\/jbc.M208724200","journal-title":"J Biol Chem"},{"key":"5146_CR15","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.18632\/oncotarget.1790","volume":"5","author":"MI Khan","year":"2014","unstructured":"Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY, Mukhtar H (2014) YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget 5:2462\u20132474. https:\/\/doi.org\/10.18632\/oncotarget.1790","journal-title":"Oncotarget"},{"key":"5146_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109867","volume":"188","author":"S Khozooei","year":"2023","unstructured":"Khozooei S, Veerappan S, Bonzheim I, Singer S, Gani C, Toulany M (2023) Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks. Radiother Oncol 188:109867. https:\/\/doi.org\/10.1016\/j.radonc.2023.109867","journal-title":"Radiother Oncol"},{"key":"5146_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1080\/15384047.2019.1638678","volume":"20","author":"JC Leung","year":"2019","unstructured":"Leung JC, Cassimeris L (2019a) Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins. Cancer Biol Ther 20:1337\u20131347. https:\/\/doi.org\/10.1080\/15384047.2019.1638678","journal-title":"Cancer Biol Ther"},{"key":"5146_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1080\/15384047.2019.1638678","volume":"20","author":"JC Leung","year":"2019","unstructured":"Leung JC, Cassimeris L (2019b) Reorganization of Paclitaxel-Stabilized Microtubule Arrays at Mitotic Entry: Roles of Depolymerizing Kinesins and Severing Proteins. Cancer Biol Ther 20:1337\u20131347. https:\/\/doi.org\/10.1080\/15384047.2019.1638678","journal-title":"Cancer Biol Ther"},{"key":"5146_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020404","author":"X Li","year":"2020","unstructured":"Li X, Strietz J, Bleilevens A, Stickeler E, Maurer J (2020) Chemotherapeutic stress influences epithelial-mesenchymal transition and stemness in cancer stem cells of triple-negative breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21020404","journal-title":"Int J Mol Sci"},{"key":"5146_CR20","doi-asserted-by":"publisher","first-page":"24171","DOI":"10.18632\/aging.203672","volume":"13","author":"PP Li","year":"2021","unstructured":"Li PP, Li RG, Huang YQ, Lu JP, Zhang WJ, Wang ZY (2021) LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p\/MTDH pathway-mediated autophagy and genomic instability. Aging 13:24171\u201324191. https:\/\/doi.org\/10.18632\/aging.203672","journal-title":"Aging"},{"key":"5146_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/0008-5472.Can-22-2709","volume":"83","author":"L Liao","year":"2023","unstructured":"Liao L, Zhang YL, Deng L, Chen C, Ma XY, Andriani L, Yang SY, Hu SY, Zhang FL, Shao ZM, Li DQ (2023) Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer. Cancer Res 83:471\u2013484. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-2709","journal-title":"Cancer Res"},{"key":"5146_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2019.03.014","volume":"452","author":"JP Lim","year":"2019","unstructured":"Lim JP, Nair S, Shyamasundar S, Chua PJ, Muniasamy U, Matsumoto K, Gunaratne J, Bay BH (2019) Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. Cancer Lett 452:119\u2013131. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.014","journal-title":"Cancer Lett"},{"key":"5146_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00268-w","volume":"9","author":"J Liu","year":"2020","unstructured":"Liu J, Qu L, Wan C, Xiao M, Ni W, Jiang F, Fan Y, Lu C, Ni R (2020) A novel \u03b22-AR\/YB-1\/\u03b2-catenin axis mediates chronic stress-associated metastasis in hepatocellular carcinoma. Oncogenesis 9:84. https:\/\/doi.org\/10.1038\/s41389-020-00268-w","journal-title":"Oncogenesis"},{"key":"5146_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53013-3","volume":"14","author":"T Liu","year":"2024","unstructured":"Liu T, Zhai C, Tian B, Li C, Han S, Wang S, Xuan M, Liu D, Zhao Y, Zhao H, Yu W, Wang J (2024) Downregulation of Roundabout guidance receptor 2 suppresses hepatocellular carcinoma progression by interacting with Y-box binding protein 1. Sci Rep 14:2588. https:\/\/doi.org\/10.1038\/s41598-024-53013-3","journal-title":"Sci Rep"},{"key":"5146_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174280","author":"R Mahmoud","year":"2022","unstructured":"Mahmoud R, Ord\u00f3\u00f1ez-Mor\u00e1n P, Allegrucci C (2022) Challenges for triple negative breast cancer treatment: defeating heterogeneity and cancer stemness. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14174280","journal-title":"Cancers (Basel)"},{"key":"5146_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366197","volume":"15","author":"K Mediratta","year":"2024","unstructured":"Mediratta K, El-Sahli S, Marotel M, Awan MZ, Kirkby M, Salkini A, Kurdieh R, Abdisalam S, Shrestha A, Di Censo C, Sulaiman A, McGarry S, Lavoie JR, Liu Z, Lee SH, Li X, Scium\u00e8 G, D\u2019Costa VM, Ardolino M, Wang L (2024) Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model. Front Immunol 15:1366197. https:\/\/doi.org\/10.3389\/fimmu.2024.1366197","journal-title":"Front Immunol"},{"key":"5146_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.yexcr.2016.07.003","volume":"346","author":"X Miao","year":"2016","unstructured":"Miao X, Wu Y, Wang Y, Zhu X, Yin H, He Y, Li C, Liu Y, Lu X, Chen Y, Shen R, Xu X, He S (2016) Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res 346:157\u2013166. https:\/\/doi.org\/10.1016\/j.yexcr.2016.07.003","journal-title":"Exp Cell Res"},{"key":"5146_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly D, Sendi MA, Kelly CM (2021) Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 12:164\u2013182. https:\/\/doi.org\/10.5306\/wjco.v12.i3.164","journal-title":"World J Clin Oncol"},{"key":"5146_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00462-7","volume":"12","author":"C Quan","year":"2023","unstructured":"Quan C, Wu Z, Xiong J, Li M, Fu Y, Su J, Wang Y, Ning L, Zhang D, Xie N (2023) Upregulated PARP1 confers breast cancer resistance to CDK4\/6 inhibitors via YB-1 phosphorylation. Exp Hematol Oncol 12:100. https:\/\/doi.org\/10.1186\/s40164-023-00462-7","journal-title":"Exp Hematol Oncol"},{"key":"5146_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113325","volume":"143","author":"S Saha","year":"2024","unstructured":"Saha S, Ghosh S, Ghosh S, Nandi S, Nayak A (2024) Unraveling the complexities of colorectal cancer and its promising therapies - an updated review. Int Immunopharmacol 143:113325. https:\/\/doi.org\/10.1016\/j.intimp.2024.113325","journal-title":"Int Immunopharmacol"},{"key":"5146_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/ijc.30075","volume":"139","author":"K Shinkai","year":"2016","unstructured":"Shinkai K, Nakano K, Cui L, Mizuuchi Y, Onishi H, Oda Y, Obika S, Tanaka M, Katano M (2016) Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models. Int J Cancer 139:433\u2013445. https:\/\/doi.org\/10.1002\/ijc.30075","journal-title":"Int J Cancer"},{"key":"5146_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115798","volume":"168","author":"M Strachowska","year":"2023","unstructured":"Strachowska M, Gronkowska K, Sobczak M, Grodzicka M, Michlewska S, Ko\u0142acz K, Sarkar T, Korszun J, Ionov M, Robaszkiewicz A (2023) I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs. Biomed Pharmacother 168:115798. https:\/\/doi.org\/10.1016\/j.biopha.2023.115798","journal-title":"Biomed Pharmacother"},{"key":"5146_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021a) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5146_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL (2021b) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5146_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/dddt.s185514","volume":"13","author":"H Tong","year":"2019","unstructured":"Tong H, Zhao K, Zhang J, Zhu J, Xiao J (2019) YB-1 modulates the drug resistance of glioma cells by activation of MDM2\/p53 pathway. Drug Des Devel Ther 13:317\u2013326. https:\/\/doi.org\/10.2147\/dddt.s185514","journal-title":"Drug Des Devel Ther"},{"key":"5146_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/cas.15280","volume":"113","author":"M Ushijima","year":"2022","unstructured":"Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M (2022) An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Cancer Sci 113:1731\u20131738. https:\/\/doi.org\/10.1111\/cas.15280","journal-title":"Cancer Sci"},{"key":"5146_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2022.106314","volume":"153","author":"Q Wu","year":"2022","unstructured":"Wu Q, Xu Y, Li X, Liu H, You T, Cai T, Yang F (2022) YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1\/PD-L1 pathway in breast cancer. Int J Biochem Cell Biol 153:106314. https:\/\/doi.org\/10.1016\/j.biocel.2022.106314","journal-title":"Int J Biochem Cell Biol"},{"key":"5146_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-024-09959-1","volume":"41","author":"C Zhang","year":"2024","unstructured":"Zhang C, Wang X, Song H, Yuan J, Zhang X, Yuan Y, Wang Z, Lei Z, He J (2024) M6A modification-mediated LIMA1 promotes the progression of hepatocellular carcinoma through the wnt-\u03b2catenin\/Hippo pathway. Cell Biol Toxicol 41:9. https:\/\/doi.org\/10.1007\/s10565-024-09959-1","journal-title":"Cell Biol Toxicol"},{"key":"5146_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6019975","author":"T Zhao","year":"2022","unstructured":"Zhao T, Zhang T (2022) Paclitaxel resistance modulated by the interaction between TRPS1 and AF178030.2 in triple-negative breast cancer. Evid Based Complement Alternat Med. https:\/\/doi.org\/10.1155\/2022\/6019975","journal-title":"Evid Based Complement Alternat Med"},{"key":"5146_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35989","volume":"10","author":"X Zhao","year":"2024","unstructured":"Zhao X, Ma Y, Luo J, Xu K, Tian P, Lu C, Song","journal-title":"Heliyon"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05146-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:32Z","timestamp":1783907012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5146"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05146-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that all experiments were performed in accordance with relevant guidelines and regulations. For clinical studies, this research protocol was reviewed and approved by The Ethics Committee of Jiangxi cancer Hospital (approval number: 2021ky021). The investigation was conducted in compliance with the Declaration of Helsinki and adhered to established ethical standards for both clinical and animal research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Our institution's committee on human research gave approval for this study, and all participants gave informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}